About Elixir Software
About Elixir Software
Vision, key contacts and partners.
There was a huge $500k time saving in back-and-forth communications ... for scientists to do more high value work.
Mid-size Biotech
Button
The ability to see progress across projects for design and synthesis helps us work out where there are holds-ups so we can make informed resourcing decisions.
Global Top 10 Large Pharma
Button
What our clients are saying ...
About Elixir Software
Vision, key contacts and partners.
Our vision is to improve R&D project delivery through better teamwork.
Elixir Software was founded in 2012 by a team of experienced research scientists and software engineers. Based in Alderley Park BioHub (Cheshire, UK), Elixir have created
iTraX, our innovative workflow management tool, setting a new industry standard for pharma / biotech focused project delivery.
Elixir Key Contacts
DAVID GREY
MBE
Executive Chairman
David is the founder and Chairman of Sheffield based diversified engineering group OSL Group Holding Ltd and a senior figure within the Cutlers’ Company. David set up his first company in 1980 and has built up his business, by acquisition and organic growth, to a group of five manufacturing companies based in the UK, USA and Germany, serving a global market.
He was awarded an MBE in the 2010 New Year’s Honours List for his Services to Industry and Regeneration in Sheffield, has served on the Sheffield City Region LEP as well as many of the other Region’s boards including Sheffield City board.
He has recently stepped down from a 7 year tenure as Chairman of Cavendish Cancer Care Charity having recently negotiated and guided the charity through a merger with Weston Park Cancer Care. The enlarged charity is now the largest cancer charity in the Sheffield Region. David’s wealth of experience serves mainly to provide advice and strategic direction to the Elixir Board as it pursues its growth strategy.
PAUL FAULDER
PhD
CEO & Co-Founder
Paul co-founded Elixir Software, with a focus on improving communication between scientists, managers, and external partners. From his industry experience in senior positions at AstraZeneca, GlaxoSmithKline, Amgen and Tularik, he set out to simplify complex workflows and enhance transparency, enabling teams to focus more on scientific discovery.
Expanding on this success, Paul led the development of advanced Design-Make-Test-Analyze (DMTA) capabilities within iTraX™, transforming how organizations manage complex experimental workflows.
As a leader in scientific collaboration technology, Paul continues to help the pharmaceutical and biotechnology industries work more transparently and efficiently, enabling researchers to spend more time on what matters most; advancing science.
MARTIN HARRISON
PhD
CTO & Co-Founder
Martin has over 20 years of software development experience in the Biotechnology and Pharmaceutical sectors including AstraZeneca, Amgen, Tularik, Protherics and Proteus Molecular Design. His activities have focussed on the integration of chemoinformatics with process management and scheduling to support the Design-Make-Test-Analyze (DMTA) cycle of the drug discovery process. He has won numerous awards including an AstraZeneca Global Innovation Award for contributing to effective management of global drug discovery projects.
At Elixir Software Ltd, Martin’s extensive experience in agile development across both Scrum and Kanban frameworks, complements his skills in test-driven development and product ownership. As the original author and product owner of the web-based
iTraX™ workflow solution, he has played a pivotal role in shaping a tool that exemplifies our commitment to improving R&D project delivery through better team working.
DAVID HOLLINSHEAD
PhD
Technical Director
David has experience of creating innovative partnerships across academia and industry. With a career spanning more than 25 years across academia, and pharmaceutical R&D in AstraZeneca, he has embraced synthetic and medicinal chemistry, the development of chemical technologies, and science policy shaping successful R&D.
As well as overseeing medicinal chemistry programmes and implementing technology platforms, David initiated early Discovery outsourcing at AstraZeneca, Alderley Park. His extensive knowledge from working with collaborators world-wide, and understanding of successful partnering underpins the business aims.
DAVID BARDSLEY
PhD
Commercial Director
David joined Elixir Software as Commercial Director, in 2020 and is responsible for the commercial strategy of the company. Through his global experience and direct interactions with people across the industry he is always seeking ways for the commercial team to serve customers better. His fundamental rule is to listen to the customer in order to discover and understand their needs.
David has been responsible for strategic commercial growth at Cresset and also previously held senior business development positions at Symyx Technologies and CambridgeSoft. David has a PhD and BSc in Microbiology from the University of Wales, Cardiff.
RAY TRAN
BEng
Head of Infrastructure
Ray brings over 25 years of experience as both a software and network engineer, having worked with several blue-chip companies on a broad range of projects. His career has been marked by a deep commitment to improving software quality and streamlining development processes. For over a decade, Ray has leveraged AWS to design and deploy robust, scalable solutions, and he has been involved with Elixir since its early days, contributing to its evolution and adoption in modern software development.
With extensive expertise in software architecture, networking, infrastructure, and task automation, Ray has successfully introduced methodologies like Test-Driven-Development (TDD) and Continuous-Integration (CI) to enhance productivity and quality across development teams. His focus on ensuring that platforms are both secure and scalable continues to drive innovation and build resilient systems that meet the demands of today’s digital landscape.
NICOLA DENNIS
Head of Global Sales
Nicola has extensive industry knowledge in SaaS solutions for the scientific market. Prior to Elixir, Nicola gained commercial experience at Torx Software (responsible for the commercial delivery of DMTA SaaS solutions to the pharmaceutical and biotechnology industry across EMEA and North America) and the Royal Society of Chemistry, as well as industry experience at AstraZeneca and GlaxoSmithKline.
Nicola has a 1st Class Master’s Degree in Medicinal Chemistry from the University of Leeds.
Elixir Partners
Cresset’s small molecule design and flexible information delivery framework is an integral component of Torx™, a complete Design-Make-Test-Analyze workflow in a single web platform, giving real-time visibility of both planned and current drug discovery projects.
Along with Cresset, Elixir Software is a founding development partner of Torx, a single web-based platform for small molecule discovery chemistry.
iTraX Applications
Chemistry
Hypothesis-driven compound synthesis tracking, with real-time visibility and prioritization, including CRO partners.
Analytical Chemistry
Hypothesis-driven compound synthesis tracking, with real-time visibility and prioritization, including CRO partners.
Study Management
Hypothesis-driven compound synthesis tracking, with real-time visibility and prioritization, including CRO partners.
Bespoke Solutions
Hypothesis-driven compound synthesis tracking, with real-time visibility and prioritization, including CRO partners.
Tailored to your scientific processes
Fully customizable to match the unique needs of your synthesis workflows, iTraX is fast to deploy with robust permission models for full control over shared information.
50+ enterprise clients boosting productivity across 4 continents
With collaborative input from major pharma clients, iTraX has allowed scientists to make better use of time and budgets for more than a decade.
Dynamic tracking: capture, track and
share hypotheses, compound
priorities and outcomes.
Stay aligned: manage resources
effectively with a real-time interface
for internal and CRO workloads.
Save time: identify compounds which have stalled and prevent duplication of synthesis targets.
External collaboration: secure, selective sharing of targets and live updates with CRO partners.
What our clients are saying ...
I refuse to manage studies without iTraX. The platform’s user-friendliness, transparency, ease of reporting, and clarity far surpass any Excel tracker, no matter how well-designed. It is integral to our operations, and I wouldn’t be nearly as effective as a study manager without it.
Associate Director
Study Management
iTraX has simplified how we work, and has increased both the transparency and efficiency of how we deliver successful science to drug projects, using intuitive software.
Graeme Moody
Drug & Safety Metabolism
I now have a customised snapshot of the sites I am responsible for .. ensuring we share the workload in adding new studies but also capturing progress on current work in a timely manner.
Stewart Jones
Pathology Sciences
Coordinating Medicinal Chemistry design ideas, prioritization and tracking of synthesis progress and compound testing for multiple projects involving many collaborating partners in different continents would be almost unthinkable without it.
Chris Walpole
SDDC Programme Director
There was a huge $500k time saving in back-and-forth communications ... for scientists to do more high value work.
Mid-size Biotech
Button
The ability to see progress across projects for design and synthesis helps us work out where there are holds-ups so we can make informed resourcing decisions.
Global Top 10 Large Pharma
Button











